NASH Clinical Trial
Official title:
A Multi-Center, Randomised, Double-blind, Placebo Controlled Phase II Clinical Study of Chiglitazar in Patients With Nonalcoholic Steatohepatitis Accompanied by Elevated Triglycerides and Insulin Resistance
The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).
Status | Recruiting |
Enrollment | 100 |
Est. completion date | February 2024 |
Est. primary completion date | February 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Before any evaluation, an informed consent form voluntarily signed by the patient must be obtained; 2. 18 -75 years old (at the time of screening visit V1), male or female; 3. MRI-PDFF = 8% ; 4. Liver stiffness value ( LSM ) 7.0-11.0kPa ; 5. Triglyceride ( TG ) =1.7mmol/L and =5.6 mmol/L; 6. HOMA-IR = 2.5 ; 7. Serum Alanine aminotransferease (ALT) = the upper limit of normal during screening. Exclusion Criteria: 1. Type 1 diabetes; 2. Any of the following for type 2 diabetes: - HbA1c = 8.5% during screening - At the time of screening, = 2 oral hypoglycemic drugs combinations - Receiving any of the following medications at screening: Thiazolidinediones (TZD) drugs, fibrates, glucagon-like peptide-1 (GLP-1) receptor agonists, insulin 3. Existing other liver diseases or history of liver diseases 4. History of transient ischemic attack or cerebrovascular accident; 5. History of myocardial infarction, or coronary angioplasty or coronary artery bypass surgery, unstable angina, heart failure (New York Heart Association NYHA grade III / IV ), or ECG signs of left ventricular hypertrophy, or serious arrhythmias ; 6. During screening, blood pressure = 160/100 mmHg ; 7. Previous or planned ( during the study period) bariatric surgery; 8. Liver transplantation history or planned liver transplantation; 9. Liver biopsy show liver cirrhosis or clinically diagnosed as cirrhosis; 10. Weight loss of more than 5% in 6 months before screening; 11. History of edema of lower limbs or whole body; 12. diagnosed as osteoporosis or any other known bone disease; 13. Donated blood or lost blood >400 ml within 8 weeks before the first medication; 14. With MRI scan contraindications; 15. In the past 5 years, there was a history of malignant tumors of any organ system; 16. Human immunodeficiency virus ( HIV ) test is positive; 17. Heavy drinking of alcohol for more than 3 months in a year; 18. Heavy smoking >30 per day within 1 year; 19. History of drug abuse in 12 months; 20. Drugs cumulatively for more than 1 month in the previous 3 months before screening, such as obeticholic acid ( OCA ), berberine; 21. Drugs that may cause liver damage for more than 2 weeks within 1 year before screening; 22. Patients received the following medications unless they have received a stable dose for at least 1 month before screening :Beta-blockers, thiazide diuretics, statins, niacin, ezetimibe, thyroid hormone; 23. The calculated eGFR < 60 mL/(min*1.73m^2 ); 24. There is clinical evidence of liver decompensation or severe liver damage; 25. Low density lipoprotein cholesterol (LDL-C) = 3.4 mmol/L during screening ; 26. Platelet < 100×10^9 /L ; 27. Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening ; 28. Pregnant or breastfeeding women. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital, Capital Medical University | Beijing | Beijing |
China | Beijing Youan Hospital, Capital Medical University | Beijing | Beijing |
China | Peking University People's Hospital | Beijing | Beijing |
China | The First Hospital of Jilin University | Ch'ang-ch'un | Jilin |
China | Foshan First People's Hospital | Foshan | Guangdong |
China | The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
China | Affiliated Hospital of Hangzhou Normal University | Hangzhou | Zhejiang |
China | First Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang |
China | The First Affiliated Hospital of Anhui Medical University | Hefei | Jiangsu |
China | The First Hospital of Lanzhou University | Lanzhou | Gansu |
China | Nanjing Second Hospital | Nanjing | Jiangsu |
China | Shanghai Tongren Hospital | Shanghai | Shanghai |
China | The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai | Shanghai |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi |
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Chipscreen Biosciences, Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage change from baseline to week 18 in liver fat content as measured by MRI using the proton density fat fraction (MRI-PDFF) | center reading for the primary endpoint | 18 weeks | |
Secondary | the change in liver fat content from baseline as shown by MRI-PDFF after 18 weeks treatment | Absolute decrease in liver fat content Proportion of patients with Liver fat content absolute decrease =5% Proportion of patients with Liver fat content relative decrease =30% proportion | 18 weeks | |
Secondary | ALT changes from baseline | changes from baseline in liver enzymes | 6,12,18 weeks | |
Secondary | FIB-4 changes from baseline | changes from baseline in Fibrosis 4 Score | 6,12,18 weeks | |
Secondary | insulin resistance changes | Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) | 6,12,18 weeks | |
Secondary | Changes from baseline in TG | blood sample | 6,12,18 weeks | |
Secondary | change from baseline in Liver stiffness measurement (LSM) with Fibroscan | to evlaute the severity of liver fibrosis | 6,12,18 weeks | |
Secondary | change from baseline in Cytokeratin18 (CK-18) | to evaluate the severity of liver damage | 6,12,18 weeks | |
Secondary | Maximum Plasma Concentration [Cmax] of chiglitazar after 1 dose, 6 weeks and 12 weeks of treatment | population PK | 0, 6,12 weeks | |
Secondary | The area under the plasma drug concentration-time curve [AUC] of chiglitazar after 1 dose, 6 weeks and 12 weeks of treatment | population PK | 0, 6,12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
Completed |
NCT02923154 -
Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
|
Phase 2 | |
Withdrawn |
NCT03980912 -
Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
|
||
Terminated |
NCT04565717 -
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
Not yet recruiting |
NCT05935488 -
Early Liver Disease Breath Detection
|
||
Recruiting |
NCT04302051 -
Assessment of Fatty Liver With Thermo-acoustic Device
|
||
Recruiting |
NCT05327127 -
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
|
Phase 2 | |
Completed |
NCT06348706 -
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
|
Phase 3 | |
Active, not recruiting |
NCT06315361 -
DIAbetes and NAFLD
|
||
Completed |
NCT03187496 -
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
|
Phase 1 | |
Not yet recruiting |
NCT06364462 -
Precise Evaluation Criteria for Histological Regression of NASH Fibrosis
|
||
Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
Recruiting |
NCT06338969 -
The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis
|
N/A | |
Active, not recruiting |
NCT05669677 -
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
|
||
Not yet recruiting |
NCT04783116 -
Plant Stanols and Liver Inflammation in Overweight and Obese Children
|
N/A | |
Recruiting |
NCT06193629 -
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
|
N/A | |
Completed |
NCT04006145 -
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
|
Phase 2 | |
Recruiting |
NCT04232293 -
Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT04925362 -
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
|
N/A |